Retrospective cohort study shows improved survival in younger patients with primary CNS lymphoma post methotrexate failure, indicating effective radiotherapy options.
Key Points
To evaluate the effectiveness of whole brain radiotherapy (WBRT) in patients with primary CNS lymphoma after methotrexate failure.
Conducted a retrospective cohort study of adults with primary CNS lymphoma treated at Memorial Sloan Kettering.
Included patients receiving WBRT for persistent or progressive disease after HD-MTX.
Overall survival calculated using Kaplan-Meier estimates and subgroup analyses performed by age and WBRT dose.
52 patients meeting the inclusion criteria had a median overall survival of 17.5 months.
Patients aged ≤50 years showed significantly improved survival compared to those >50 years.
No significant survival difference was observed between low and high WBRT doses.